To validate the findings in cell lines carrying intrinsic IDH mutants, we investigated the role of TET1/2 in the DNA damage response and tumorigenicity using patient-derived glioma stem cells (GSCs), BT054, and BT142. The gene discussed is TET1; the disease is central nervous system cancer.